Lophius Biosciences Launches Interactive T Cell Tools Product Finder and Online Order Portal
Lophius Biosciences GmbH, a privately held biotech company focusing on the development and marketing of innovative T cell-based research tools and diagnostic systems for functional assessment of pathogen/disease-reactive T cells, has launched of its new T Cell Tools product line together with its new e-commerce online order portal. The new web-based customer interface at www.Lophius.com has been designed to provide an intuitive product selection and online order platform accelerating the ability of customers to quickly identify and select products from Lophius’ continuously growing portfolio.
T Cell Tools comprise selected research reagents to allow easy and reliable T cell stimulation, as well as robust quantification and monitoring of cell mediated immune responses (CMI). Different antigens from various pathogens with a current focus on the human cytomegalovirus (HCMV) and Epstein-Barr Virus (EBV) are well coordinated and validated to jointly contribute to a standardized and reliable read-out system. Hence, the individual product modules of T Cell Tools offer modular and complementary solutions for optimal assay performance.
Today, T Cell Tools include, amongst, peptide pools, lysates an proteins, a panel of T-activated antigens - complete proteins that are formulated using Lophius’ proprietary T-activation technology platform facilitating uptake and processing of the proteins via the canonical MHC class-I cross-presentation pathway. As a result, clinically relevant effector cells of the CMI such as CD4- and CD8-positve T cells as well as NK, and NKT cells will be activated. Optionally, customers may also combine their antigens with a matching IFN-gamma ELISPOT T-Track basic kit to reach maximum sensitivity and specificity upon measuring pathogen specific T cells.
Lophius aims to quickly expand the panel of antigens, antibodies, conjugates and read-out options to offer its customers a very comprehensive panel of relevant and well coordinated tools in near future to booster T cell research. Customers include researchers and clinicians in the field of immunology, infectious diseases, transplantation, clinical virology, oncology, autoimmune diseases, gynecology, and intensive care who need optimal performance by using either the standardized in-vitro diagnostic kit T-Track CMV or an individually compiled T cell activity assay based on the robust T-Track technology.
“We are very excited to announce the launch of our e-commerce portal as we believe it will provide our customers greater access to Lophius’ products at their convenience,” said Dr Robert Phelps, CEO of Lophius Biosciences. “With our intuitive product finder, consumers can browse and order some of the most innovative T cell products on the market” added Prof. Ralf Wagner, Chairman of the Board.
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance